Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxifloxacin Hydrochloride

FDA-approved product (tablet, oral), marketed as Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Moxeza and 3 more.

Registered studies
50+
Lab records
54
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxifloxacin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Eye infection
  • Infection
  • Pneumonia
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA14; WHO ATC S01AE07

Repurposing investigation

Moxifloxacin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 28 of 28 lab records
  • M. tuberculosis: measured active in 24 of 25 lab records
Open Moxifloxacin Hydrochloride in ChEMBL Registered studies below
Show the 54 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxifloxacin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

    NCT07595042 · start 2026-10-30

    Registered record
    Registry ID
    NCT07595042
    Conditions
    Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-30
    Completion
    2029-10-22
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants

    NCT07708272 · start 2026-07-30

    Registered record
    Registry ID
    NCT07708272
    Conditions
    Myelofibrosis
    Interventions
    TQ05105 tablets; Placebo tablets; Moxifloxacin Hydrochloride Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2026-07-30
    Completion
    2027-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis
    InterventionTQ05105 tablets; Placebo tablets; Moxifloxacin Hydrochloride Tablets
    PhasePhase 1
    Registry statusActive not recruiting

  • A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

    NCT07305831 · start 2026-01-22

    Registered record
    Registry ID
    NCT07305831
    Conditions
    Healthy
    Interventions
    Ulonivirine; Moxifloxacin; Ulonivirine Placebo; Moxifloxacin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-01-22
    Completion
    2026-04-09
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionUlonivirine; Moxifloxacin; Ulonivirine Placebo; Moxifloxacin Placebo
    PhasePhase 1
    Registry statusCompleted

  • Shortened Regimen for Drug-susceptible TB in Children

    NCT06253715 · start 2025-01-15

    Registered record
    Registry ID
    NCT06253715
    Conditions
    Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    Interventions
    Isoniazid; Rifampin; Pyrazinamide; Ethambutol; Rifapentine; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2027-09-30
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Lymph Node; Mycobacterium Tuberculosis
    InterventionIsoniazid; Rifampin; Pyrazinamide; Ethambutol +2 more
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

    NCT06411860 · start 2024-09-12

    Registered record
    Registry ID
    NCT06411860
    Conditions
    Basic Science
    Interventions
    Placebo; Olpasiran; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-09-12
    Completion
    2024-12-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasic Science
    InterventionPlacebo; Olpasiran; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II

    NCT06271772 · start 2024-07-01

    Registered record
    Registry ID
    NCT06271772
    Conditions
    Bacterial Keratitis
    Interventions
    Difluprednate Ophthalmic; Rose Bengal; Moxifloxacin Ophthalmic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-07-01
    Completion
    2027-02-28
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis
    InterventionDifluprednate Ophthalmic; Rose Bengal; Moxifloxacin Ophthalmic
    PhasePhase 3
    Registry statusActive not recruiting

  • A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

    NCT06162286 · start 2023-11-17

    Registered record
    Registry ID
    NCT06162286
    Conditions
    Community-acquired Bacterial Pneumonia
    Interventions
    Omadacycline; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-11-17
    Completion
    2025-11-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Bacterial Pneumonia
    InterventionOmadacycline; Moxifloxacin
    PhasePhase 3
    Registry statusUnknown

  • An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

    NCT05867147 · start 2023-04-26

    Registered record
    Registry ID
    NCT05867147
    Conditions
    Cystic Fibrosis
    Interventions
    Vanzacaftor; Vanzacaftor Placebo; Moxifloxacin; Moxifloxacin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-04-26
    Completion
    2023-06-14
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionVanzacaftor; Vanzacaftor Placebo; Moxifloxacin; Moxifloxacin Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

    NCT05830071 · start 2023-03-29

    Registered record
    Registry ID
    NCT05830071
    Conditions
    Asthma; Chronic Obstructive Pulmonary Disease (COPD)
    Interventions
    CHF5993; CHF5259; Moxifloxacin 400mg; CHF5993 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-03-29
    Completion
    2023-10-13
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Chronic Obstructive Pulmonary Disease (COPD)
    InterventionCHF5993; CHF5259; Moxifloxacin 400mg; CHF5993 Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants

    NCT05668936 · start 2023-01-03

    Registered record
    Registry ID
    NCT05668936
    Conditions
    Non-alcoholic Steatohepatitis
    Interventions
    Cotadutide; Cotadutide-placebo; Moxifloxacin; Moxifloxacin-placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-01-03
    Completion
    2023-03-10
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-alcoholic Steatohepatitis
    InterventionCotadutide; Cotadutide-placebo; Moxifloxacin; Moxifloxacin-placebo
    PhasePhase 1
    Registry statusTerminated

  • Elagolix for Fertility Enhancement Clinical Trial

    NCT04039204 · start 2022-01-15

    Registered record
    Registry ID
    NCT04039204
    Conditions
    Endometriosis; Unexplained Infertility
    Interventions
    Elagolix; Ortho Cyclen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-01-15
    Completion
    2023-08-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Unexplained Infertility
    InterventionElagolix; Ortho Cyclen
    PhasePhase 2
    Registry statusCompleted

  • The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

    NCT05655689 · start 2021-12-31

    Registered record
    Registry ID
    NCT05655689
    Conditions
    Bacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    Interventions
    Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp; Voriconazole 1%; Natamycin 5% + voriconazole 1%; Natamycin 5%+ ceftazidime 5% + vancomycin 5%; Voriconazole 1% + ceftazidime 5% + vancomycin 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2023-01-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    InterventionMoxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Premature Discontinuation of Contraceptive Implants

    NCT04828824 · start 2021-06-18

    Registered record
    Registry ID
    NCT04828824
    Conditions
    Contraception Behavior
    Interventions
    Ethinyl Estradiol / Norgestimate Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-18
    Completion
    2025-11-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception Behavior
    InterventionEthinyl Estradiol / Norgestimate Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

    NCT04722978 · start 2021-04-20

    Registered record
    Registry ID
    NCT04722978
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Gemcitabine and carboplatin plus antibiotic (moxifloxacin); Gemcitabine combined with carboplatin plus placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-04-20
    Completion
    2026-07
    Enrolment
    228

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionGemcitabine and carboplatin plus antibiotic (moxifloxacin); Gemcitabine combined with carboplatin plus placebo
    PhasePhase 3
    Registry statusRecruiting

  • To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

    NCT04281342 · start 2020-01-14

    Registered record
    Registry ID
    NCT04281342
    Conditions
    Healthy Subjects
    Interventions
    Aprocitentan 25 mg; Aprocitentan 100 mg; Matching placebo; Moxifloxacin control to establish assay sensitivity
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-14
    Completion
    2021-09-03
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionAprocitentan 25 mg; Aprocitentan 100 mg; Matching placebo; Moxifloxacin control to establish assay sensitivity
    PhasePhase 1
    Registry statusCompleted